← Leaderboards
Andrew J Wiemer
University Of Connecticut Storrs
$4,146,227
Attributed
$5,363,585
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $954.4K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,363,585 · 4
By mechanism
R01$4,960,903 · 3
R21$402,682 · 1
Top collaborators
- Olga Vinogradova5 shared
- Raman Bahal2 shared
Most similar at University Of Connecticut Storrs
Same institution · by research overlap
- Raman Bahal$2,703,154
- Laijun Lai$5,623,060
Others in their field
Top investigators on “Antigens”
- Barton F Haynes · Duke University$488,918,563
- Lawrence Corey · Fred Hutchinson Cancer Center$325,880,100
- Dennis R. Burton · Scripps Research Institute$291,395,948
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$245,204,950
- Jeffrey P Krischer · University Of South Florida$208,289,343
- Dan H. Barouch · Fred Hutchinson Cancer Center$124,506,327
Research focus
AntigensPhosphorusT-LymphocyteMediatingCancer CellBiologicalResponseReceptorSmall MoleculeProductionCellsImmuneImmune ResponseCytokineImmunotherapyMalignant NeoplasmsBindingCytolysisAffectIn Vitroî³î´ T CellsImmune CheckpointLigandsCell Line
Grant awards (15)
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy$370,809
R01 · FY2025 · CA · contact PI
Role of immune modulating butyrophilins in gamma delta T cell activation$368,411
R01 · FY2024 · AI · contact PI
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy$347,829
R01 · FY2024 · CA · contact PI
Development of pHLIP-phosphoantigen conjugates for lymphoma therapy$214,513
R21 · FY2024 · CA · contact PI
Role of immune modulating butyrophilins in gamma delta T cell activation$411,881
R01 · FY2023 · AI · contact PI
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy$354,363
R01 · FY2023 · CA · contact PI
Development of pHLIP-phosphoantigen conjugates for lymphoma therapy$188,169
R21 · FY2023 · CA · contact PI
Role of immune modulating butyrophilins in gamma delta T cell activation$411,881
R01 · FY2022 · AI · contact PI
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy$350,029
R01 · FY2022 · CA · contact PI
Role of immune modulating butyrophilins in gamma delta T cell activation$419,931
R01 · FY2021 · AI · contact PI
Role of immune modulating butyrophilins in gamma delta T cell activation$419,931
R01 · FY2020 · AI · contact PI
Regulation of gamma delta T cell immunoediting by novel phosphoantigens$371,265
R01 · FY2018 · CA · contact PI
Regulation of gamma delta T cell immunoediting by novel phosphoantigens$377,822
R01 · FY2017 · CA · contact PI
Regulation of gamma delta T cell immunoediting by novel phosphoantigens$377,585
R01 · FY2016 · CA · contact PI
Regulation of gamma delta T cell immunoediting by novel phosphoantigens$379,166
R01 · FY2015 · CA · contact PI